

Lupin enhances gastroenterology portfolio and expands presence in emerging markets

18 December 2025 | News

Plasil® is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders that affect millions of patients



Global pharma major Lupin Limited has announced that its subsidiaries in the Philippines (Multicare Pharmaceuticals) and Brazil (MedQuimica) have signed an exclusive licensing agreement with Neopharmed Gentili S.p.A, an Italian pharmaceutical company, for marketing and promotional rights for the Gastroenterology brand, Plasil® (*metoclopramide*), in their respective markets.

This agreement will enhance Lupin's gastroenterology portfolio and expand its presence in emerging markets. Neopharmed will oversee product supply in the Philippines, ensuring quality and compliance with global standards. In Brazil, production will be shifted to Medquimica's manufacturing facility.

"Our partnership with Neopharmed represents a significant milestone in Lupin's commitment to expand access to Plasil, one of the most potent anti-emetic treatments, across key emerging markets. Our extensive local presence, regulatory expertise, and strong commercial capabilities in the Philippines and Brazil, together with Neopharmed's distribution network and reach, will broaden patient access and deliver meaningful health outcomes," said Fabrice Egros, President of Corporate Development, Lupin.

“We are pleased to partner with Lupin to bring Plasil® to two strategic and rapidly growing markets, such as Brazil and the Philippines. This agreement reflects our commitment to expanding Neopharmed’s international footprint, while leveraging Lupin’s strong local presence to ensure that Plasil® is available to every patient in need,” said Matteo Meazzini, Director of Business Development, Neopharmed Gentili.